Skip to main content
Premium Trial:

Request an Annual Quote

Linkage Biosciences Raises $2M in Series A Round

NEW YORK (GenomeWeb News) – Linkage Biosciences has raised $2 million in a Series A round of financing, the molecular diagnostics firm said today.

Linkage Bio said the funding round was led by Greenhouse Capital Partners and James R. Fisher, managing member of Fisher Capital Corp. II, a firm that works exclusively with Kohlberg Kravis Roberts.

The firm expects to use the proceeds to support continued development and marketing of Linakge Bio's molecular diagnostic products. It is focused on human leukocyte antigen typing for organ transplantation but also is developing products for other transplant diagnostics and complex genetic disorders.

San Francisco-based Linkage Bio also said that Rebecca Bishop, who is an executive at Affymetrix, and Pascal Villiger of CalSTRS' private equity division, have joined its board of directors.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.